MA40378A - Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine - Google Patents
Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléineInfo
- Publication number
- MA40378A MA40378A MA040378A MA40378A MA40378A MA 40378 A MA40378 A MA 40378A MA 040378 A MA040378 A MA 040378A MA 40378 A MA40378 A MA 40378A MA 40378 A MA40378 A MA 40378A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- derivatives
- tetrahydroquinolein
- cholesterol level
- synthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne un procédé pour la préparation d'intermédiaires synthétiques qui peuvent être utilisés dans la préparation de dérivés de la tétrahydroquinoléine, lesquels dérivés ont une activité inhibitrice à l'encontre de la protéine de transfert de cholestéryle (cetp), présentent des effets d'augmentation du taux de cholestérol hdl et de diminution du taux de cholestérol ldl, et peuvent être utilisés pour le traitement et/ou la prévention de maladies telles que des maladies artérioscléro
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 | ||
| PCT/NL2015/050555 WO2016024858A1 (fr) | 2014-08-12 | 2015-07-29 | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40378A true MA40378A (fr) | 2017-06-21 |
| MA40378B1 MA40378B1 (fr) | 2022-10-31 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40378A MA40378B1 (fr) | 2014-08-12 | 2015-07-29 | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (fr) |
| EP (2) | EP3180314B1 (fr) |
| JP (1) | JP6670310B2 (fr) |
| KR (1) | KR102572626B1 (fr) |
| CN (1) | CN107108558B (fr) |
| AR (1) | AR101509A1 (fr) |
| AU (1) | AU2015302407B2 (fr) |
| BR (1) | BR112017002873B1 (fr) |
| CA (1) | CA2958040C (fr) |
| CL (1) | CL2017000367A1 (fr) |
| CY (1) | CY1125574T1 (fr) |
| DK (1) | DK3180314T3 (fr) |
| EA (1) | EA034357B1 (fr) |
| ES (1) | ES2926775T3 (fr) |
| HR (1) | HRP20221061T1 (fr) |
| HU (1) | HUE059947T2 (fr) |
| IL (1) | IL250525B (fr) |
| LT (1) | LT3180314T (fr) |
| MA (1) | MA40378B1 (fr) |
| MX (1) | MX367908B (fr) |
| PL (1) | PL3180314T3 (fr) |
| PT (1) | PT3180314T (fr) |
| RS (1) | RS63575B1 (fr) |
| SG (1) | SG11201701077XA (fr) |
| SI (1) | SI3180314T1 (fr) |
| SM (1) | SMT202200385T1 (fr) |
| TW (1) | TWI691490B (fr) |
| WO (1) | WO2016024858A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4125911B1 (fr) | 2021-03-05 | 2024-04-24 | NewAmsterdam Pharma B.V. | Obicetrapib pour le traitement de démences |
| MX2024001170A (es) | 2021-07-26 | 2024-05-14 | Newamsterdam Pharma B V | Tratamiento de personas hiporreactivas a his. |
| IL314031A (en) | 2021-12-30 | 2024-09-01 | Newamsterdam Pharma B V | Obicetrapib and sglt2 inhibitor combination |
| PE20251749A1 (es) | 2022-07-05 | 2025-07-09 | Newamsterdam Pharma B V | Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos |
| TW202416994A (zh) | 2022-08-22 | 2024-05-01 | 荷蘭商新阿姆斯特丹製藥公司 | 固定劑量醫藥組合物及其用途 |
| EP4661865A1 (fr) | 2023-02-07 | 2025-12-17 | NewAmsterdam Pharma B.V. | Traitement combiné d'obicétrapib et d'ézétimibe et compositions pharmaceutiques à dose fixe |
| WO2025059594A1 (fr) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | Méthodes de traitement de l'hypercholestérolémie familiale hétérozygote (hefh) |
| WO2025093129A1 (fr) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Traitement et prévention de la dégénérescence maculaire liée à l'âge à l'aide d'un inhibiteur de la cetp |
| WO2025093436A1 (fr) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Traitement et prévention de la dégénérescence maculaire liée à l'âge à l'aide d'un inhibiteur de cetp |
| WO2025146262A1 (fr) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib destiné à être utilisé dans le traitement d'hémoglobinopathies |
| WO2025146415A1 (fr) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Amélioration de caractéristiques de plaque athéroscléreuse avec de l'obicetrapib |
| WO2026062050A1 (fr) | 2024-09-17 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib destiné à être utilisé dans des méthodes de traitement d'un sujet ayant une hypercholestérolémie familiale hétérozygote (hefh) et/ou une maladie cardiovasculaire athéroscléreuse (ascvd) |
| WO2026063944A1 (fr) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib pour le traitement de démences |
| WO2026062049A1 (fr) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V., | Obicetrapib pour le traitement des démences |
| WO2026087915A1 (fr) | 2024-10-25 | 2026-04-30 | Newamsterdam Pharma B.V. | Traitement et prévention de la septicémie ou d'autres réponses inflammatoires dérégulées à l'aide d'un inhibiteur de la cetp obicetrapib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| ES2256461T3 (es) * | 2001-04-30 | 2006-07-16 | Pfizer Products Inc. | Compuestos utiles como intermediarios de derivados de 4-aminoquinolina. |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
| TW200808731A (en) * | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
-
2015
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 CA CA2958040A patent/CA2958040C/fr active Active
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/fr not_active Ceased
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 SM SM20220385T patent/SMT202200385T1/it unknown
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active Active
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/fr active Active
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/fr active Pending
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es active IP Right Grant
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
-
2022
- 2022-09-22 CY CY20221100631T patent/CY1125574T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40378B1 (fr) | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA45985A (fr) | Inhibiteurs de diacylglycérol acyltransférase 2 | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| MA40290A1 (fr) | Agents immunorégulateurs | |
| MA43131B1 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| MA41013A (fr) | Compositions comprenant des souches bactériennes | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA38284A1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MX2018004043A (es) | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. | |
| MA39972A (fr) | Composés et compositions d'induction de la chondrogenèse | |
| EA202090555A1 (ru) | Фармацевтические композиции, содержащие антитела к бета-амилоиду | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues |